阿托伐他汀对原发性高血压早期肾损害患者hs-CRP和ET-1的影响

Effects of atorvastatin on the serum high-sensitivity C-reactive protein and endothelin-1 in essential hypertensive patients with early renal damage

目的观察阿托伐他汀对原发性高血压早期肾损害患者血清超敏C反应蛋白(hs-CRP)和内皮素-1(ET-1)的影响。方法将86例经尿微量白蛋白(mALb)及尿β2微球蛋白(β2-MG)检测证实有早期肾功能损害的原发性高血压患者分为治疗组和对照组,两组均口服降压药物,治疗组加服阿托伐他汀钙片10 mg/d,两组疗程均为12 w。治疗前后分别检测患者尿mALb、尿β2-MG、血清hs-CRP、血清ET-1。结果治疗后两组尿mALb及β2-MG均明显下降(P<0.01),且治疗组与对照组比较下降更显著(P<0.05);治疗组治疗后血清hs-CRP、ET-1水平明显下降(P<0.01),与对照组比较也有显著性差异(P<0.05)。结论阿托伐他汀可减轻原发性高血压早期肾损害,其作用机制可能与抑制炎症因子和保护血管内皮功能有关。

Objective To observe the effects of atorvastatin on the serum high-sensitivity C-reactive protein and endothelin-1 in essential hypertensive（EH） patients with early renal damage. Methods Eighty six EH patients with early renal damage, who were confirmed by the detection of urine micro-albumin（mALb） and urine β2-microglobulin（ I32-MG）, were randomly divided into treatment group and control group. Both groups orally took the hypotensive drugs, while the treatment group also took atorvastatin calcium （10 mg each day）. The course of treatment was 12 w. Before and after the treatment,the patients＇urine mALb,urine β2-MG, serum hs-CRP, and ET-1 were detected. Results After the treatment, the levels of mALb and I32-MG in both two groups significantly decreased （P 〈 0. 01 ）, and the treatment group decreased more significantly（ P 〈 0.05 ）. The levels of serum hs-CRP and serum ET-1 in the treatment group decreased after the treatment, and there were significant difference between the two groups （ P 〈 0.05 ）. Conclusion Atorvastatin can relieve early renal damage in patients with essential hypertension. Its mechanism may be related to the inhibition of inflammatory factor and protection of vascular endothelia.